• Abstract
• Full-Text PDF [233 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Zhu, Q
• Xu, W
• Tao, M
• [+] on Google Scholar
• Zhu, Q
• Xu, W
• Tao, M
• [+] on PubMed
• Zhu, Q
• Xu, W
• Tao, M

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Cancers 2010, 2(2), 721-739; doi:10.3390/cancers2020721

Review

Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis

Qiu-Li Zhu ¹ , Wang-Hong Xu ^1,*  and Meng-Hua Tao ^2,*

¹ Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China ² Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214, USA

* Authors to whom correspondence should be addressed.

Received: 23 March 2010; in revised form: 13 April 2010 / Accepted: 26 April 2010 / Published: 28 April 2010

(This article belongs to the Special Issue Biomarkers: Oncology Studies)

Download PDF Full-Text [233 KB, uploaded 28 April 2010 09:20 CEST]

Abstract: In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.

Keywords: metabolic syndrome; breast cancer; epidemiology; biomarkers; prognosis

Article Statistics

Cite This Article